BRCA2 and ovarian cancer: Pathogenic germline variants in these genes confer a high risk for developing breast and/or ovarian cancer that can reach 72% and 44% for BRCA1 mutation carriers and 69% (for breast cancer) and 17% (for ovarian cancer) for those with BRCA2 pathogenic alterations (5–7).